Cargando…

Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck

Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor. The role of cetuximab is paramount in several subsets of head and neck cancer. In particular, the EXTREME study has indicated cetuximab as the only drug to improve survival when associated with cisplatin a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perri, Francesco, Longo, Francesco, Ionna, Franco, Caponigro, Francesco
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886337/ https://www.ncbi.nlm.nih.gov/pubmed/20616911

Ejemplares similares

Management of HPV-Related Squamous Cell Carcinoma of the Head and Neck: Pitfalls and Caveat
por: Perri, Francesco, et al.
Publicado: (2020)

Boosting the Immune Response with the Combination of Electrochemotherapy and Immunotherapy: A New Weapon for Squamous Cell Carcinoma of the Head and Neck?
por: Longo, Francesco, et al.
Publicado: (2020)

Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy
por: Perri, Francesco, et al.
Publicado: (2019)

Genetics and management of locally advanced carcinomas of the head and neck: role of altered fractionation radiotherapy
por: Perri, Francesco, et al.
Publicado: (2018)

Cancer Cell Metabolism Reprogramming and Its Potential Implications on Therapy in Squamous Cell Carcinoma of the Head and Neck: A Review
por: Perri, Francesco, et al.
Publicado: (2022)

Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial
por: Caponigro, Francesco, et al.
Publicado: (2016)

Patients affected by squamous cell carcinoma of the head and neck: A population particularly prone to developing severe forms of COVID-19
por: Perri, Francesco, et al.
Publicado: (2021)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance
por: Iannelli, Federica, et al.
Publicado: (2020)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies
por: Ionna, Franco, et al.
Publicado: (2021)

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma
por: MASEKI, SHINICHIRO, et al.
Publicado: (2013)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

Surgical oncology of the head and neck district during COVID-19 pandemic
por: Salzano, Giovanni, et al.
Publicado: (2021)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
por: Kono, Scott A., et al.
Publicado: (2012)

Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck
por: BAUMAN, JESSICA, et al.
Publicado: (2013)

The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism
por: Pickhard, Anja, et al.
Publicado: (2014)

Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma
por: Setúbal Destro Rodrigues, Maria Fernanda, et al.
Publicado: (2018)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Taberna, Miren, et al.
Publicado: (2019)

Matrisomal genes in squamous cell carcinoma of head and neck influence tumor cell motility and response to cetuximab treatment
por: Goh, Kah Yee, et al.
Publicado: (2022)

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
por: Chen, Tien-Hua, et al.
Publicado: (2022)

Oral lichen planus and other confounding factors in narrow band imaging (NBI) during routine inspection of oral cavity for early detection of oral squamous cell carcinoma: a retrospective pilot study
por: Guida, Agostino, et al.
Publicado: (2019)

Cetuximab in the treatment of head and neck cancer: preliminary results outside clinical trials
por: Dequanter, Didier, et al.
Publicado: (2010)

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma
por: Espinosa-Cotton, Madelyn, et al.
Publicado: (2019)

Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
por: Uozumi, Shinya, et al.
Publicado: (2018)

Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma
por: Kondo, T, et al.
Publicado: (2016)

EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma
por: Chaudhary, Ritu, et al.
Publicado: (2023)

Concurrent Radiotherapy with Carboplatin and Cetuximab for the Treatment of Medically Compromised Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
por: Saigal, Kunal, et al.
Publicado: (2014)

Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa
por: Yang, Chuan-Chien, et al.
Publicado: (2022)

An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer
por: Cavalieri, Stefano, et al.
Publicado: (2022)

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status
por: Baysal, Hasan, et al.
Publicado: (2020)

New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Alberti, Andrea, et al.
Publicado: (2022)

Management of recurrent nasopharyngeal carcinoma: current perspectives
por: Perri, F, et al.
Publicado: (2019)

Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck
por: Schmitz, Sandra, et al.
Publicado: (2015)

Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck
por: Hoellein, Alexander, et al.
Publicado: (2011)

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
por: Tejani, Mohamedtaki A, et al.
Publicado: (2010)

Cetuximab: its unique place in head and neck cancer treatment
por: Specenier, Pol, et al.
Publicado: (2013)

Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
por: Patel, Akshar N., et al.
Publicado: (2012)

Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Charalambakis, Nikolaos, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_s5dpf4kbqnc7cljcc2b8bnh9v0